Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF + venetoclax + cladribine + cytarabine for relapsed/refractory or newly diagnosed non-responsive AML
ChiCTR2600135042Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Nov 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, cladribine, cytarabine and filgrastim in acute myeloid leukemia (AML), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
venetoclaxcladribinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600135042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135042.